Home Blog Page 713

Fosun Pharma Announces 2025 Annual Results

By
Advertorial Desk
-

Innovation and Globalization Propel Fosun Pharma’s High-Quality Growth

SHANGHAI, March 24, 2026 /PRNewswire/ — On 24 March, 2026, Fosun Pharma (“the company”, stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual operating results (the reporting period).

Powered by the dual engines of innovation and globalization, Fosun Pharma achieved total operating revenue of RMB 41.662 billion, up 1.45% year-on-year. Of this, revenue from innovative drugs reached RMB 9.893 billion, rising 29.59% year-on-year; overseas revenue amounted to RMB 12.977 billion, growing 14.87% year-on-year. Net profit attributable to shareholders of the parent company was RMB 3.371 billion, up 21.69% year-on-year; recurring net profit attributable to shareholders of the parent company amounted to RMB 2.34 billion, increasing 1.12% year-on-year; and net cash flow generated from operating activities reached RMB 5.213 billion, up 16.45% year-on-year, further consolidating the foundation for high-quality development.

Innovative Drugs Emerge as Core Growth Engine

Revenue from innovative drugs hit RMB 9.893 billion, accounting for 33.16% of pharmaceutical business revenue, becoming the core engine of performance growth. Total R&D investment for the year amounted to RMB 5.913 billion, up 6.46% year-on-year, of which R&D investment related to innovative pharmaceuticals reached RMB 4.303 billion, a year-on-year increase of 15.98%, accounting for 80.26% of pharmaceutical business R&D investment.

High-intensity R&D investment has been translated into fruitful results. During the reporting period, 16 indications of 7 innovative drugs were approved for marketing in China and overseas markets; marketing applications for 6 innovative drug candidates were accepted, and nearly 40 innovative drug clinical trials received approval from China and overseas regulatory authorities; and multiple core products entered key clinical phases, laying a solid pipeline foundation for subsequent commercial growth. Additionally, 5 new innovative drugs were included in the 2025 National Reimbursement Drug List (NRDL), and the CAR-T therapy Yikaida (axicabtagene ciloleucel injection) was successfully listed in the first edition of the Commercial Insurance Innovative Drug Catalog. This not only improves patient access to innovative drugs but also further unlocks the volume potential of commercialization.

Building Differentiated Clinical Pipeline Advantages

Fosun Pharma focuses on innovative drugs as its development priority. Centering on the three core therapeutic areas of oncology (solid tumors, hematologic tumors), immune inflammation and neurodegenerative diseases, the Company continuously strengthens its pipeline construction through in-house R&D, collaborative development and licensing-in.

Oncology: In 2025, Fosun Pharma further strengthened the layout of its innovative pipeline around key indications such as breast cancer and lung cancer. The company’s self-developed small-molecule innovative drug Fumaining® (luvometinib Tablet) received approval for two indications, filling the gap in the treatment of rare tumors in China; the innovative small-molecule CDK4/6 inhibitor Futuoning® (fovinaciclib citrate capsules) was launched for two indications in China, bringing a brand-new treatment option for breast cancer patients; the anti-PD-1 monoclonal antibody Serplulimab Injection was approved in Europe and multiple emerging markets for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), becoming the first anti-PD-1 monoclonal antibody to receive such approval in the EU and accelerating the company’s globalization pace; antibody and ADC drugs such as HLX43 and HLX22 entered key clinical phases, continuously improving the echelon of the oncology pipeline. The marketing application for the second CAR-T product Brexucabtagene Autoleucel was accepted.

Immune Inflammation and Chronic Diseases: The licensed-in first-in-class innovative drug Wantile (Tenapanor Hydrochloride Tablets) was successfully approved, providing a new treatment option for chronic kidney disease patients on dialysis in China. Steady clinical progress was made for core products such as FXS7553.

Neurodegenerative diseases: Opicapone Capsules, a treatment for Parkinson’s disease, was launched in the Boao Pilot Zone for innovative drugs. Fosun Insightech accelerated product upgrading and indication expansion for its Magnetic Resonance-guided Focused Ultrasound (MRgFUS) system. Sodium Oligomannate Capsule was incorporated into the Company’s Alzheimer’s disease innovative drug pipeline, with post-marketing confirmatory clinical trials underway. AR1001, an in-licensed asset, has advanced into global multi-center Phase 3 clinical trials. These initiatives further enriched the Company’s product pipeline in the neurodegenerative disease sector.

Breakthroughs in Cutting-Edge Technologies and Two-way Licensing

On the basis of consolidating core technology platforms including antibodies, ADCs, small molecules, and cell therapy, Fosun Pharma is strategically investing in advanced fields such as radiopharmaceuticals and small interfering RNA (siRNA). The radiopharmaceutical project SRT-007 successfully initiated Phase I clinical trials, establishing a preliminary “imaging diagnosis – targeted therapy” integrated R&D pathway; in cell therapy, the autologous dual-target CAR-T product FKC289 had its clinical trial application accepted by the NMPA, continuously empowering the reserve of follow-on innovative products.

In 2025, Fosun Pharma’s global resource integration capability has been significantly enhanced. The total upfront payment from out-licensing reached over US$260 million in the whole year, with potential milestone payments exceeding US$ 3.8 billion. Among them, the global licensing project of the GLP-1 target YP05002 garnered an upfront payment of US$150 million and potential total payments of US$2.085 billion, fully confirming the global competitiveness of the company’s innovative R&D. In terms of collaborative development, Fosun Pharma entered into a joint development agreement with Teva for FXB0871 and established original innovation cooperation with a fund under Aditum Bio. Meanwhile, Fosun Pharma introduced multiple overseas original drugs, including Akynzeo (netupitant and palonosetron hydrochloride capsules), Pu Rui Ni (pretomanid tablets) , and Daxxify (botulinum toxin type A for injection), through licensing-in, achieving marketing approval for them in China.

Globalization Moves Towards “System-centric Globalization”

In 2025, Fosun Pharma’s international development achieved a strategic upgrade from “product-centric going global” to “system-centric globalization”, making comprehensive breakthroughs in innovative R&D, production quality, registration and access, commercialization and academic influence, and building a global operation network covering markets such as China, the United States, Europe, Africa, India and Southeast Asia. In 2025, the company’s overseas revenue reached RMB 12.977 billion, accounting for 31.15% of the total revenue, increased by 3.64 percentage points year-on-year.

Fosun Pharma has built a global R&D and production synergy registration capability featuring “leading breakthroughs in Europe and the US, and in-depth cultivation in emerging markets”. The core innovative drug Serplulimab Injection has been approved for marketing in more than 40 countries and regions worldwide. In the United States, the bridging study for first-line ES-SCLC has completed enrolment, with a Biologics License Application (BLA) submission planned for 2026. Biosimilars such as Denosumab have successively obtained approvals from the FDA and the EU, marking that the quality system and registration capability of the biologic drug platform have been certified to international standards; the small-molecule innovative drug Fumaining® received Priority Review status from the Saudi Food and Drug Authority (SFDA) in Saudi Arabia, becoming an important fulcrum to leverage the Middle East and global markets.

Seventeen of Fosun Pharma’s workshops/production lines in China have passed GMP certifications of mainstream regulatory markets such as the US, the EU and the WHO. The relevant biologic drug production lines have realized regular supply to the global market, covering China, Europe, Latin America, Southeast Asia, India and other markets. Multiple injection production lines of India’s Gland Pharma have passed certifications in Europe, the US, Japan and Australia, providing a solid guarantee for the stability and quality controllability of the global supply chain.

Fosun Pharma has formed a mature overseas go-global model of “independent operation + licensing authorization” running in parallel, with over 6,000 commercial personnel worldwide and established a marketing network covering over 40 countries and regions in Africa; the controlling subsidiary Sisram’s marketing network covers over 110 countries and regions, while Breas covers over 50 countries and regions.

ESG Governance Recognized by Global Authorities

While achieving high-quality development of its core business, in 2025, Fosun Pharma’s MSCI ESG rates were upgraded to “AA”, retained its Hang Seng ESG rating of “A-” and was selected into the 2025 Fortune China ESG Influence List, being the only Chinese pharmaceutical enterprise on the list.

“In 2025, Fosun Pharma firmly implemented its corporate strategy of Innovation Driven, Deep Globalization and AI Embracement, achieving high-quality growth powered by innovative drugs and globalization.” Chen Yuqing, Chairman of Fosun Pharma said, “Looking ahead, Fosun Pharma will always focus on unmet clinical needs, continue to innovate, and further deepen its layout in core therapeutic areas such as oncology, immune inflammation and neurodegenerative diseases. It will integrate innovative resources from a global perspective, drive operational upgrading with digital intelligence, and strive to become a world-leading integrator of medical innovation, creating long-term value for shareholders and providing more high-quality and accessible medicines and healthcare solutions for patients.”

About Fosun Pharma

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.

Looking ahead, guided by the strategy of “Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.

For more information, please visit the company website: https://www.fosunpharma.com/en/

 

 

Databricks Enters Security Market with Launch of Lakewatch: New Open, Agentic SIEM

By
Advertorial Desk
-

New product enables unlimited and unified data, petabyte-scale threat detection and investigations at up to 80% lower TCO

SAN FRANCISCO, March 24, 2026 /PRNewswire/ — Databricks, the Data and AI company, today announced Lakewatch, a new open, agentic SIEM (Security Information and Event Management) designed to help organizations defend against increasingly sophisticated agent attackers. Lakewatch unifies security, IT, and business data into a single, governed environment for AI detection and response. With open formats and an open ecosystem, Lakewatch enables customers to ingest, retain and analyze unprecedented volumes of multi-modal data, while slashing costs and eliminating vendor lock-in. Security teams gain complete visibility across the enterprise and can deploy defensive security agents to automate threat detection and response at massive scale. Lakewatch is now available in Private Preview.

Defending at Machine Speed
AI threats are evolving at a speed and complexity that goes beyond human-led defenses. Attackers can now deploy agents to continuously scan systems, discover vulnerabilities, and execute coordinated attacks at machine speed. Defenders remain constrained by incomplete data, manual workflows, and siloed architectures. High ingestion costs force them to discard up to 75% of their data. This creates a dangerous asymmetry: attackers use AI agents to attack anywhere, while defenders see only a fraction of their own data and are limited by how fast their teams can react.

Lakewatch closes this gap by enabling organizations to unify all their data in open formats so they can analyze years of data cost-effectively without moving or duplicating it. This includes multi-modal data like video and audio to identify social engineering, insider threats, and anomaly detection. With Lakewatch, swarms of AI agents automate detection, triage, and threat hunting to meet machine-speed attackers with machine-speed defense.

“Security teams can no longer rely on manual workflows to outpace AI-driven attacks,” said Ali Ghodsi, Co-Founder and CEO of Databricks. “With Lakewatch, we are giving enterprises a new open data architecture and agentic capabilities to replace stagnating SIEM tools. Defenders must have even better visibility and speed than today’s agent attackers.”

Open, Agentic SIEM for Enterprise Speed and Scale
Lakewatch is designed to deliver agentic security atop the scale of an open security lakehouse. Key features include:

  • Agentic Triage and Investigation: Build, optimize, and deploy custom security agents with Agent Bricks to handle complex workflows end-to-end. Agents parse and enrich telemetry across hundreds of formats to reduce Mean Time to Detect & Respond (MTTD/R), while remaining inside the secure, governed environment where data already lives.
  • Automated Security Intelligence: Integrated with Genie, Lakewatch automates triage, plans multi-step approaches, and helps enterprises reduce alert fatigue, leaving more time for analysts to focus on high-impact threats.
  • Open Ecosystem: Unify all structured and unstructured security data on one open, cloud-agnostic platform that integrates with any tool to identify social engineering, insider threats, and anomaly detection. Databricks’ new Open Security Lakehouse Ecosystem is a fast-growing group of leading security vendors and delivery partners, including Anvilogic, Arctic Wolf, Cribl, Obsidian, Okta, Palo Alto Networks, 1Password, Panther, Proofpoint, Rearc, Slack, TrendAI, Wiz (now part of Google Cloud), and Zscaler.
  • Detection-as-Code: Manage detections as code with automated testing and deployment to ensure defense is always version-controlled and verified.
  • Governance and Compliance at Scale: Enable compliance and consistent policy enforcement with Unity Catalog. Access cost-effective, long-term retention out of the box, helping global enterprises meet rigorous new mandates such as NIS2 and DORA.

Enterprise organizations use Lakewatch to unify their data and detect threats faster with AI. Lakewatch customers include industry leaders like Adobe and Dropbox.

“As the volume of security data grows, organizations need new ways to analyze and act on that information quickly and at scale,” said Karthik Venkatesan, Security Engineering Lead at Adobe. “Databricks provides the foundation needed to move from data-driven to AI-driven approaches for security operations, and Lakewatch is an important step toward bringing security intelligence closer to where data already lives.”

Deepening Partnership with Anthropic
Building on the success of the two companies’ existing strategic partnership, Databricks and Anthropic are deepening their collaboration to deliver agentic security operations. Anthropic Claude models help power Lakewatch, using Claude’s advanced reasoning capabilities to correlate signals across security, IT, and business data to surface threats faster. Anthropic also uses Databricks for its own security lakehouse to gain complete visibility across its security and business data and detect threats earlier.

Expanding Security Leadership with Antimatter and SiftD.ai Acquisitions
To advance its open, agentic SIEM approach, Databricks is announcing the acquisitions of both Antimatter and SiftD.ai. Antimatter was founded by UC Berkeley security researchers who laid the foundation for provably secure authentication and authorization for AI agents. SiftD.ai, founded by the creator of Splunk’s Search Processing Language (SPL) and lead architects of Splunk’s search stack, will bring deep expertise in large-scale detection engineering and modern threat analytics.

Availability
Lakewatch is now available in Private Preview. Read more about Lakewatch on the Databricks blog.

About Databricks

Databricks is the Data and AI company. More than 20,000 organizations worldwide — including adidas, AT&T, Bayer, Block, Mastercard, Rivian, Unilever, and over 60% of the Fortune 500 — rely on Databricks to build and scale data and AI apps, analytics and agents. Headquartered in San Francisco with 30+ offices around the globe, Databricks offers a unified platform that includes Lakebase, Genie, Agent Bricks, Lakeflow, Lakehouse, and Unity Catalog. To learn more, follow Databricks on LinkedIn, X, YouTube, and Instagram.

Contact: Press@databricks.com

 

L&G and Manulife Wealth & Asset Management Announce Strategic Global Partnership

By
Advertorial Desk
-

LONDON and TORONTO, March 24, 2026 /PRNewswire/ — L&G and Manulife Wealth & Asset Management (Manulife WAM) today announced a long-term multi-faceted strategic partnership. It spans Distribution, Investment Management, and Product Development to enhance the global distribution reach of both firms, allowing them to meet growing client demand for comprehensive wealth and retirement solutions across Europe, Asia, the U.S.A., Canada, and Bermuda.

The partnership is designed to leverage Manulife WAM’s asset management capabilities and broad distribution channels in North America and Asia, along with L&G’s strengths as a global asset manager and its leading position in annuities and reinsurance.

The multi-phase partnership is anticipated to cover a number of asset classes across public and private markets including Alternative Credit, Fixed Income, Multi-asset Solutions, and Real Estate, Infrastructure, and Natural Capital, as well as investment products such as Exchange Traded Funds (ETFs).

This partnership underscores the joint commitment to delivering diverse investment solutions and expanding access to differentiated strategies for institutional, retirement, and retail clients globally. It also reflects the shared strategic growth ambitions of Manulife WAM and L&G, with both firms prioritizing scaling new capabilities and strengthening their presence in key international markets.

L&G is a global asset manager with around £1.2 trillion in assets under management (AUM). It is a major global investor across private and public markets including in UK and European Real Estate, Index & ETFs, Active Fixed Income, Multi-asset, Liquid Alternatives, Cash and Liquidity funds, and Infrastructure. In 2025, it set out its plan to deliver international growth through a build, partner or buy strategy.

Manulife WAM is a highly diversified global wealth and asset management firm with more than CAD$1.3 trillion in assets under management and administration (AUMA)i. The firm’s strength comes from the diversity of its global asset management expertise and distribution capabilities—operating in 20 geographies, including 10 in Asia, and distributing innovative investment solutions across complementary distribution channels including Retail (intermediary), Retirement, Institutional, and Wealth.  

Eric Adler, CEO of L&G Asset Management, stated, “This is another example of L&G consolidating its position as a global asset manager and delivering on our strategy to build, partner or buy as we drive international growth.”

“Our new partnership with Manulife Wealth & Asset Management will broaden investor access to L&G’s public and private markets investment solutions and expand our global distribution reach. We see immense potential in our complementary investment capabilities working together to address increasing demand for retirement and wealth solutions,” concluded Mr. Adler.

Paul Lorentz, CEO of Manulife WAM, commented, “We see tremendous opportunities for both organizations in this strategic partnership as we leverage our complementary strengths: our Canadian, U.S. and Asian asset management capabilities, along with breadth in distribution channels in North America and Asia, with L&G’s distribution capabilities and strength in global asset management. This strategic partnership will support the expansion of our product platform to bring a more comprehensive and competitive offering to all markets where we currently operate – reinforcing our commitment to be the number one choice for customers around the world.”

Implementation is expected across a range of initiatives that will roll out over a number of years.

About Manulife Wealth & Asset Management
As part of Manulife Financial Corporation, Manulife Wealth & Asset Management’s mission is to make decisions easier and lives better by helping people invest confidently for a more secure financial future. Our strength comes from the diversity of our global asset management expertise and distribution capabilities. Our global investment teams span equities, fixed income, alternative credit, private markets, and multi-asset solutions. We provide investment, financial advice, and retirement plan services to millions of individuals, institutions, and retirement plan members worldwide. At the heart of our approach are three cultural pillars: Partner for Progress, Trust through Transparency, and Intellectual Curiosity. These values shape how we build long-term relationships, develop differentiated investment strategies, and empower advisors and clients to achieve meaningful financial outcomes. Whether through cutting-edge technology, AI innovation, personalized advice, or sustainable stewardship, Manulife Wealth & Asset Management is a trusted partner helping clients navigate complexity and invest with confidence. Not all offerings are available in all jurisdictions. For additional information, please visit manulifeim.com.

About L&G
Established in 1836, L&G is one of the UK’s leading financial services groups and a major global investor, with around £1.2 trillion in total assets under management (as at FY25) of which c. 43% is international. We have a highly synergistic business model, which continues to drive strong returns. We are a leading player in Institutional Retirement, in Retail Savings and Protection, and in Asset Management through both public and private markets. Across the Group, we are committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

This document contains forward-looking statements by Manulife within the meaning of the “safe harbor” provisions of Canadian provincial securities laws and the U.S. Private Securities Litigation Reform Act of 1995 including with respect the expected benefits of the strategic partnership. Although Manulife believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements.

Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from expectations include but are not limited to: the anticipated benefits from the intended strategic partnership and changes in general economic and market conditions, laws and regulations.

Additional information about material risk factors that could cause actual results to differ materially from expectations may be found in Manulife’s most recent annual and interim reports and elsewhere in Manulife’s filings with Canadian and U.S. securities regulators.  The forward-looking statements in this document are, unless otherwise indicated, stated as of the date hereof. Manulife does not undertake to update any forward-looking statements, except as required by law.

Forward-looking statements include statements regarding the expected scope, timing and benefits of the intended strategic partnership and any initiatives contemplated, all of which are subject to change and to the satisfaction of applicable conditions, approvals and definitive documentation.

_______________________________

i As of December 31, 2025.

Media Contacts:

Elizabeth Bartlett 
Manulife Wealth & Asset Management
elizabeth_bartlett@manulife.com

Andrew Gates 
L&G
andrew.gates@lgim.com

2026 Wealth for Good in HK Summit concludes, showcasing city’s appeal as global family-office hub

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 24 March 2026 – The fourth edition of the Wealth for Good in Hong Kong (WGHK) Summit concluded today (March 24) under the theme “Building Lasting Legacies”, bringing together over 400 influential top family office decision-makers, next-generation successors, industry leaders and pioneers from around the world to explore new perspectives for multi-generational succession and sustained wealth growth for global family offices.

The Financial Secretary, Mr Paul Chan, speaks at the Wealth for Good in Hong Kong Summit Gala Dinner today (March 24).
The Financial Secretary, Mr Paul Chan, speaks at the Wealth for Good in Hong Kong Summit Gala Dinner today (March 24).

Co-organised by the Financial Services and the Treasury Bureau and Invest Hong Kong (InvestHK), the WGHK Summit drew family office decision-makers from Asia, Europe, the Americas, the Middle East, Oceania, and Africa to Hong Kong for in-depth discussions on topics ranging from cross-generational wealth management and cultural legacy to technological innovation and philanthropy.

Delivering remarks at the gala dinner, the Financial Secretary, Mr Paul Chan, said, “Facing risks and uncertainty, investors diversify by necessity. Families seeking to preserve their legacy look for a safe haven—not merely a place to park capital, but a place with institutional strengths, legal clarity and credible commitments.

“Hong Kong is not only a safe harbour. It is also a city of business opportunities, and a platform for growth, for connection and for the purposeful deployment of capital. For families from around the world, Hong Kong is, no doubt, the best gateway to tap the enormous opportunities on the Mainland. International capital and investors are optimistic about Hong Kong. Our stock market performed strongly last year. And our asset and wealth management is also thriving. We are also opening up new frontiers, including gold and commodity trading, as well as fixed income and currency markets, which will further enrich our financial ecosystem.”

The Deputy Financial Secretary, Mr Michael Wong, delivered welcome remarks at the Summit and said, “Hong Kong is a perfect base to support the prudent diversification of the investments by family offices. The world is getting more uncertain. Many conflicts are escalating and proceeding in a manner that is increasingly worrying and concerning. Against this global backdrop, Hong Kong offers something that is quite rare and precious. Under ‘one country, two systems’, Hong Kong provides an economic and business environment with policy predictability and institutional trust. Our common law legal system, independent judiciary, open economy, free flow of capital, freely convertible currency, and simple tax regime all work together to provide a welcoming and dependable home for wealth that lasts through generations.”

Speaking at the Summit, the Secretary for Financial Services and the Treasury, Mr Christopher Hui, said, “As we gather under the visionary banner of ‘Building Lasting Legacies’, I want to frame our discussions through a lens that truly defines Hong Kong: Safe, Stable and Sophisticated. It is the bedrock upon which global family offices are choosing to build, preserve and multiply generational wealth. Each session of today’s Summit has reinforced one fundamental truth: Hong Kong offers the safe harbour, the policy stability and the sophisticated ecosystem that ambitious families need to turn vision into lasting impact. Our Government remains fully committed to strengthening this foundation to drive Hong Kong as a nexus of legacies and innovation.”

Mr Hui highlighted that wealth succession is not only about growing fortune, but also about carrying forward core values across generations. He said that the Hong Kong Academy for Wealth Legacy is turning vision into action through its flagship philanthropic initiative, Impact Link (iLink). Since its launch, iLink has organised 17 workshops and seminars, equipping and inspiring over 700 family participants with the knowledge and confidence to begin their philanthropic journeys. Last June, the launch of the iLink Online Portal connected 55 family partners and strategic partners who together nominated 12 non-governmental organisations and charitable projects, offering families international connectivity and information collection for structured, informed decision making in charitable giving. Mr Hui described it as “Wealth for Good in its purest and most inspiring form”.

The Director-General of Investment Promotion at InvestHK, Ms Alpha Lau, said, “Hong Kong stands as a leading global hub for wealth management, innovation, culture, and philanthropy. The WGHK Summit’s gathering of family leaders from across the globe fully embodies Hong Kong’s role as a super-connector. InvestHK will continue to serve as a bridge, providing comprehensive strategic support and on-the-ground facilitation for global families, transforming the collaborative opportunities sparked at the Summit into tangible outcomes of ‘Building Lasting Legacies’ in Hong Kong.”

This year’s WGHK Summit featured one fireside chat and three panel discussions. The opening fireside chat on “Beyond the Scoreboard: Sports, Philanthropy, and Building Lasting Legacies” explored how sports and philanthropy can complement each other to create positive impacts. The three panel discussions, themed “Family Office Playbook: Governance, Capital, and Values Across Generations”, “Lasting Culture: Owning Demand, Building Communities, Creating Legends”, and “Lasting Change: AI, Robotics, and Building the Future Together”, invited helmsmen of internationally renowned family businesses, brand leaders, and tech pioneers to delve into cross-generational wealth planning and family governance, brand building, and how cutting-edge technologies are co-building the future.

A number of distinguished guest speakers shared their insights at the Summit.

Co-CEO and Chief Scientific Officer of Insilico Medicine, Dr Ren Feng, said, “Hong Kong plays a pivotal role at the intersection of two strategic pillars – frontier technology and life sciences. Built on a strong research base, an efficient capital market, and a forward-looking commitment to AI and technologies, Hong Kong not only provides fertile ground for companies like Insilico Medicine to translate breakthrough technologies into real-world impact but also serves as a distinctive global hub for capital and family offices – bridging long-term value investors with cutting-edge biopharmaceutical innovation. At WGHK2026, we showcased how AI is reshaping the traditional drug discovery and development paradigm and explored how family office investors can play a catalytic role in this technological transformation – together shaping the future of global health.”

“Hong Kong’s decision to position itself as a cultural hub where East truly meets West makes it the natural springboard for family-run heritage brands,” says Representative of Major Shareholder of Leica Camera AG, Mr Maximilian Kaufmann. “World-class infrastructure and seamless connectivity link people, ideas and businesses here, giving companies like ours the ideal platform to share our story across Asia. Having grown up inside Leica and learning from a father who always shouldered responsibility, I see Hong Kong as the place where tradition and entrepreneurship can thrive side by side.”

Founder of Yao Foundation, former Chairman of Chinese Basketball Association and NBA All-Star, Mr Yao Ming, said, “Hong Kong is where East and West meet, Chinese and other cultures converge. Those who are more inclusive, more open, and more diverse will have more opportunities, and are more likely to spark the greatest inspiration and innovation. That is Hong Kong’s most distinctive and valuable advantage. I’m happy to continue serving as a bridge between East and West – bringing different visions and people together, and supporting one another to succeed, so that everyone benefits.”

The Summit kicked off with a spectacular and powerful joint performance by the Diocesan Boys’ School Chinese Drum Team and robotic drummers that quickly caught the eyes of the floor. Seeing youngsters collaborating with smart technology on stage perfectly echoed the Summit’s theme of “Building Lasting Legacies”. This harmonious fusion of traditional artistry and frontier innovation symbolised how the next generation is embracing their mission to forge the future with innovative thinking.

It was a successful conclusion for the Summit with a gala dinner where worldwide family office decision-makers and industry leaders continued their exchanges against the backdrop of Victoria Harbour, delving into cross-generational succession, asset allocation, and collaborative opportunities. The two-day programme covered three major areas – wealth management, cultural branding, and smart technology – facilitating numerous cross-sector dialogues and exploration of potential collaborations, further consolidating Hong Kong’s leading position as a global family-office hub.
Hashtag: #WGHK

The issuer is solely responsible for the content of this announcement.

GFTN, The University of Western Australia’s QUISA Research Centre, and ST Engineering Partner to Advance Quantum-Safe Financial Infrastructure through Q-FINEX

By
Advertorial Desk
-

PERTH, Australia, March 24, 2026 /PRNewswire/ — Global Finance & Technology Network (GFTN), The University of Western Australia’s Quantum Information, Simulation and Algorithms (QUISA) research group, and ST Engineering today announced a strategic partnership to jointly advance Q-FINEX, a quantum-enabled financial infrastructure initiative designed to accelerate the financial sector’s readiness for the quantum era. 

A milestone moment at Black Swan Summit Australia in Perth as GFTN, UWA’s QUISA, and ST Engineering officially launch Q-FINEX. Photo credit: GFTN
A milestone moment at Black Swan Summit Australia in Perth as GFTN, UWA’s QUISA, and ST Engineering officially launch Q-FINEX. Photo credit: GFTN

Unveiled at the Black Swan Summit Australia 2026 in Perth, Q-FINEX represents a significant milestone in translating quantum computing from scientific promise into real-world financial applications. The initiative is designed as a dedicated Quantum Finance Industry Experimentation testbed, bringing together three critical enablers: specialised research capability, a global network facilitating the gathering of use cases and an ecosystem, and a proven implementation partner.

“These elements work together to bridge the gap between research, real-world use cases, and implementation pathways,” said Sopnendu Mohanty, Group CEO of GFTN, adding, “This collaboration is strengthened by ST Engineering, our global implementation partner that will help translate the test of experiments to real world implementations in the financial industry and contributing crucial domain expertise.”

Through this collaboration, GFTN and ST Engineering will bridge the gap between quantum research and practical deployment, enabling financial institutions to experiment, validate and implement quantum-enabled solutions in a structured, real-world environment. The partnership combines GFTN’s global network of central banks, financial institutions, regulators and fintech innovators with ST Engineering’s deep expertise in secure digital infrastructure, cybersecurity and advanced technologies. GFTN will facilitate engagement with ecosystem partners to identify and develop real-world financial use cases, where ST Engineering’s capabilities can be applied, accelerating pathways to adoption and deployment of quantum-safe solutions.

Said Tan Bin Ru, President of Enterprise Digital at ST Engineering, “Quantum is not only about chasing the future; it is also about preparing for it. Our innovations and expertise in delivering secured, mission-critical systems empower us to partner with financial institutions as they transition to achieve quantum resilience.”

About Q-FINEX

Q-FINEX is designed to address three topical challenges facing the financial sector today:

  • Rising market complexity, through advanced quantum-enabled modelling for faster and more precise decision-making;
  • Evolving cybersecurity threats, via quantum-safe encryption to safeguard financial systems against future risks;
  • The rapid growth of digital assets, enabling enhanced pricing, risk management, and security of digital asset exposures.

At its core, Q-FINEX enables financial institutions to test real-world use cases, experiment with hybrid classical and quantum algorithms using actual financial data, and evaluate the infrastructure required for a quantum-enabled future.

“This initiative aims to bridge the gap between quantum computing research and real-world deployment by transforming cutting-edge quantum algorithms into practical use cases. The testbed will support financial institutions worldwide in evaluating quantum-enabled solutions using real-world data,” said Professor Jingbo Wang, Founder and Director of the Quantum Information, Simulation and Algorithms (QUISA) research group at The University of Western Australia.

The partnership, formalised at the launch ceremony held at the second edition of the Black Swan Summit Australia at Winthrop Hall, The University of Western Australia, was attended by representatives from the key partners, including:

  • Mr. Ravi Menon, Chairman, GFTN
  • Professor Amit Chakma, Vice-Chancellor, The University of Western Australia
  • Mr. Sopnendu Mohanty, Group CEO, GFTN
  • Professor Jingbo Wang, Director, UWA QUISA
  • Ms. Tan Bin Ru, President of Enterprise Digital at ST Engineering

Advancing Quantum Readiness in Finance

The partnership underscores the growing global urgency for quantum readiness as financial institutions prepare for the transformative impact of next-generation computing on encryption, risk modelling, optimisation and digital trust frameworks.

Through Q-FINEX, GFTN continues to catalyse collaboration across financial services, academia, and technology providers, shaping trusted, quantum-safe digital infrastructure for the next era of finance.

About the Global Finance & Technology Network (GFTN)

Global Finance & Technology Network (GFTN) is a Singapore-headquartered not-for-profit organisation established by the Monetary Authority of Singapore (MAS) in 2024. With offices Tokyo and Berlin, GFTN’s mission is to bridge policy, capital, and technology to build financial systems that are resilient, efficient, and inclusive. GFTN operates through its commercial subsidiaries, GFTN Services and GFTN Capital. GFTN Services, through GFTN Connect, hosts global forums across five continents that bring together market makers and policymakers from over 130 countries, and GFTN Solutions offers comprehensive advisory, technology solutions, and capacity building to governments and the private sector. GFTN Capital will be a venture capital firm investing in growth-stage FinTechs globally. For more information, please visit www.gftn.co

About QUISA

The Research Centre for Quantum Information, Simulation and Algorithms (QUISA), hosted at The University of Western Australia, fosters collaboration and entrepreneurship, bringing together academic staff, research students, government and industrial partners to develop innovative quantum solutions to tackle otherwise intractable problems and complex phenomena.

About ST Engineering

ST Engineering is a global technology, defence and engineering group with a diverse portfolio of businesses across the aerospace, smart city, defence and public security segments. The Group harnesses technology and innovation to solve real-world problems, enabling a more secure and sustainable world. Headquartered in Singapore, it has operations spanning Asia, Europe, the Middle East and the U.S., serving customers in more than 100 countries. ST Engineering reported revenue of over $12b in 2025 and ranks among the largest companies listed on the Singapore Exchange. It is a component stock of MSCI Singapore, FTSE Straits Times Index and Dow Jones Best-in-Class Asia Pacific Index. Follow ST Engineering on LinkedIn.

Michter’s Distillery to Release 2026 Edition of Two Legacy Series Whiskeys: Shenk’s Homestead & Bomberger’s Declaration

By
Advertorial Desk
-

LOUISVILLE, Ky., March 24, 2026 /PRNewswire/ — This April Louisville based Michter’s Distillery will release its 2026 Shenk’s Homestead Kentucky Sour Mash Whiskey and its 2026 Bomberger’s Declaration Kentucky Straight Bourbon. The two whiskeys will be available in limited quantities. 

Michter's Distillery to Release 2026 Edition of Two Legacy Series Whiskeys: Shenk's Homestead & Bomberger's Declaration
Michter’s Distillery to Release 2026 Edition of Two Legacy Series Whiskeys: Shenk’s Homestead & Bomberger’s Declaration

In 1753, Swiss Mennonite farmer John Shenk founded Shenk’s Distillery in Pennsylvania. This distillery was later renamed Bomberger’s Distillery in the 1800s before its name changed again to Michter’s Distillery in the mid-20th Century. It is this heritage that the Michter’s Legacy Series honors.

“Each year our production team looks forward to working on these special releases of Shenk’s and Bomberger’s,” commented Michter’s President Joseph J. Magliocco. “They really highlight the creativity of our distillers. While there is a commonality in each of these whiskeys from year to year, every release is a bit different because of experimentation done at the distillery.”

While describing the 2026 Shenk’s release, Michter’s Master Distiller Dan McKee said, “In addition to this whiskey being a bit rye forward, we used caramel malted barley which offers a nice caramel bread pudding note that balances the beautiful spice. The cooperage we use includes some 24-month air dried French oak from the Vosges forest as well as some 60-month air dried American oak, and this helps impart a special character to this Shenk’s release.”

Michter’s Master of Maturation Andrea Wilson commented, “It is a wonderful opportunity to work on Shenk’s and Bomberger’s with Dan and the team at Michter’s. The prospect is not just to try something new, but to explore how aroma, depth, flavor, complexity and finish can be influenced through changing variables to enhance the drinking experience. This year’s Bomberger’s again brings delight with the whiskey’s hallmark Chinquapin Oak coupled with the addition of some Hungarian Oak thereby creating an intriguing, rich chocolate decadence around the cherry and spice attributes synonymous with Chinquapin. Both types of oak were naturally seasoned and air dried for three years with a custom toast and char. It is super exciting to see how the integration of oak flavors can enhance the sophistication and depth of the tasting journey.”

Shenk’s Homestead is 91.2 proof (45.6% ABV) and has a U.S. suggested retail price of $110. Bomberger’s Declaration is 108 proof (54% ABV) and has a U.S. suggested retail price of $120.

In October 2025, Michter’s became the first whiskey to be named in three consecutive years The World’s Most Admired Whiskey by an international academy of voters convened by UK-based Drinks International. Michter’s has a rich and long legacy of offering traditional American whiskeys of uncompromising quality. With each of its limited production offerings aged to its peak maturity, Michter’s highly acclaimed portfolio includes bourbon, rye, sour mash whiskey, and American whiskey. For more information about Michter’s, please visit michters.com and follow us on Instagram, Facebook, and X.

Contact:
Joseph J. Magliocco
+1 (502) 774-2300 x580
jmagliocco@michters.com

 

BIOTRONIK Leaps Forward with Next‑Generation Leadless Pacing

By
Advertorial Desk
-
  • International BIO-LivIQ Study Will Generate Evidence for Global LivIQ Leadless Pacemaker Approvals
  • Far-Field Sensing and AV-Synchronous Pacing Performance Will be Validated by Real World Clinical Data

BERLIN, March 24, 2026 /PRNewswire/ — BIOTRONIK today announced the initiation of its global pivotal study evaluating the LivIQ leadless pacemaker system. This next-generation single‑device solution is designed to deliver atrioventricular (AV)-synchrony using advanced electrical far‑field sensing.

BIOTRONIK LivIQ Catheter Handle
BIOTRONIK LivIQ Catheter Handle

First implantations within this study have been completed at the Kokura Memorial Hospital in Kitakyushu, Japan and the National Cerebral and Cardiovascular Center (NCVC) in Osaka, Japan. “The BIOTRONIK leadless pacemaker system was remarkably straightforward to implant. Catheter navigation and deployment were intuitive, helping us to achieve excellent device positioning and initial results,” said Dr. Kenji Ando, Department of Cardiology at Kokura Memorial Hospital.

“I am pleased to see a highly compelling option emerging for a single device leadless pacemaker, promised to deliver strong AV-synchrony and long-term device performance,” added Dr. Kengo Kusano, Study Principal Investigator at NCVC.

As a prospective multicenter clinical investigation, the BIO-LivIQ study will enroll 325 patients across 60 sites worldwide. The trial will evaluate device safety, pacing performance, AV-synchrony behavior, and quality-of-life outcomes to generate the evidence required for global regulatory submissions.

LivIQ continues BIOTRONIK’s long‑standing commitment to physiologic pacing. It uses proven far‑field sensing technology to electrically detect atrial activity and enable a single‑device VDD mode. This advanced sensing approach supports reliable AV synchrony across a broad range of clinical scenarios. Equally important, LivIQ’s highly maneuverable catheter is designed for precise control and predictable placement, creating a smooth, streamlined implantation experience.  

“We are one step closer to providing clinicians with a more intuitive and capable single‑device solution in leadless pacing,” said Dr. Andreas Hecker, Chief Technology Officer at BIOTRONIK. “LivIQ brings together two key advances that address distinct clinical needs. It combines an easy‑to‑handle catheter design that simplifies implantation, and a novel sensing concept that enhances therapy performance across more scenarios.” 

Clinicians seek solutions to avoid complications related to the pacemaker’s pocket, infection risks, and an invasive experience. Leadless pacing continues to emerge as an important therapy option and is designed to address these growing needs.

CAUTION – Investigational device. Limited to federal (United States) law to investigational use.

About BIOTRONIK

For over 60 years, BIOTRONIK has stood at the forefront of medical technology, pioneering breakthrough innovations that are transforming the lives of millions affected by heart disease and chronic pain. Rooted in a deep purpose to seamlessly harmonise technology with the human body, we engineer trusted, life-changing therapies through our advanced active implants in Cardiac Rhythm Management, Monitoring, and Neuromodulation, while providing cutting-edge solutions in Electrophysiology. From creating Germany’s first pacemaker in 1963 to breaking new ground in digital technologies and Conduction System Pacing today, BIOTRONIK is continuously raising the bar for quality, performance, and innovation. Headquartered in Berlin, our global reach spans over 100 countries across the Americas, EMEA, and Asia—bringing bold, future-ready solutions that are shaping the next generation of medical technology.    

Athena Intelligence Launches India Push Amid Rising Cross-Border Corporate Risk

By
Advertorial Desk
-

Aditya Jain appointed to lead expansion, backed by senior Indian defence and law enforcement figures

GENEVA, March 24, 2026 /PRNewswire/ — Athena Intelligence, the Geneva-based corporate investigations and risk advisory firm, is expanding into India as demand accelerates for cross-border intelligence and financial crime expertise.

Aditya Jain, newly appointed Associate Partner at Athena Intelligence India
Aditya Jain, newly appointed Associate Partner at Athena Intelligence India

The firm has appointed Aditya Jain as Associate Partner to lead its India operations, marking a strategic move into one of the world’s fastest-evolving corporate risk environments.

India’s corporate risk landscape is intensifying rapidly. More than 265 million cyberattacks were recorded in 2025 alone¹, while Indian organisations face over 2,000 cyberattacks per week – significantly higher than global averages². The country now accounts for 12.4% of global malware attacks³, highlighting the scale and international nature of threats facing businesses.

Athena Intelligence, which specialises in complex, multi-jurisdictional investigations, is positioning itself to support Indian corporates, financial institutions, law firms, and High Net Worth Individuals navigating these risks.

Aditya Jain – Associate Partner, Athena Intelligence India
Aditya Jain is a Strategic Intelligence, Cyber & Technology Advisor with experience across corporate investigations and AI-driven risk engagements in South Asia and international markets. As Founder & CEO of a Geneva-based narrative intelligence platform, he combines global expertise with local institutional insight.

“India is at a tipping point when it comes to corporate risk. The threats are increasingly international – cross-border fraud, reputational attacks, cyber intrusions – and they require an international response. Athena Intelligence brings exactly that capability, and I am committed to making it accessible to Indian businesses, institutions, and individuals who deserve world-class protection.” – Aditya Jain, Associate Partner, Athena Intelligence

The expansion is supported by senior advisors from India’s defence and law enforcement community.

Senior Advisory Support
Colonel Shashank Kaushal, Indian Army (Ret.), serves as Senior Advisor to Athena Intelligence. A decorated senior army officer with a distinguished record in strategic operations and national security. He has been a military Adviser at the highest level. Colonel Kaushal advises Athena Intelligence and Aditya Jain on security-related investigations and provides senior-level access across India’s defence and intelligence community.

Dr. Rajendar Pal Singh, Former Director General, Economic Offences Wing (EOW) & Special Investigation Team (SIT), Uttar Pradesh (2018–2021), and Former Deputy Director General, Narcotics Control Bureau (NCB), New Delhi (2013–2018), serves as Strategic Advisor to Aditya Jain. Dr. Singh brings unparalleled expertise in economic crime, anti-corruption, and narcotics investigations, and provides Aditya Jain with deep institutional insight across India’s law enforcement, regulatory, and policy eco system.

“Aditya Jain is the right person to represent Athena Intelligence in India. His investigative expertise, cyber and technology background, and deep institutional relationships make him uniquely equipped to build what we believe will become India’s most credible cross-border investigations practice. Athena Intelligence is proud to plant its flag in India with Aditya leading the charge.” – Jonas Rey, CEO, Athena Intelligence

Athena Intelligence will offer services including due diligence, anti-money laundering investigations, corporate intelligence, cyber risk advisory, and cross-border asset tracing.

Notes to Editors:

References:

1. Economic Times / Seqrite Cyber Threat Report (2025–2026) – India recorded over 265 million cyberattacks
2. Check Point Software Technologies, State of Cyber Security in India 2025 – Indian organisations face ~2,011 cyberattacks per week, higher than global averages
3. Acronis Cyber Threat Report – India accounts for 12.4% of global malware attacks, ranking among the most targeted countries worldwide

About Athena Intelligence:
Founded in 2019, Athena Intelligence operates across Europe, Asia, and the Americas, supporting clients on complex investigations involving fraud, corruption, and reputational risk.

Web: www.athenaintelligence.ch

1...712713714...6,492Page 713 of 6,492